CNS Pharmaceuticals, Inc. CNSP
4.93
(0.22)
(4.27%)
as of 25 Sep
- Market cap
- $7.5M
- P/E
- 0.0×
Follow CNSP
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
5.81 | 1.98 | 0.89 | 5.86 |
Net Debt/EBITDA |
3.03 | 1.20 | 0.59 | 7.43 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.68 | 0.51 | 0.94 | 1.37 | |
Capex/Depreciation |
0.00 | (18.20) | (3.26) | (0.34) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(3.89) | (6.93) | (6.89) | (0.52) | |
Cash per Share |
17.65 | 16.26 | 4.37 | 2.92 | |
Shareholders Equity per Share |
17.73 | 10.21 | 0.10 | 2.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.73 | 10.21 | 0.10 | 2.66 | |
Free Cash Flow |
(2.17) | (3.07) | (4.65) | (3.54) | |
Working Capital |
9.43 | 4.00 | (0.50) | 18.19 | |
Capital Expenditures |
— | (0.02) | (0.01) | 0.00 | |
Net Current Asset Value |
9.43 | 4.00 | (0.50) | 18.19 | |
| Other line items | |||||
Quick Ratio |
5.04 | 1.76 | 0.64 | 5.35 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.89) | (6.89) | (6.88) | (0.52) | |
Capex per Share |
0.00 | (0.04) | (0.01) | 0.00 | |
Average Payables |
2.98 | 2.99 | 3.46 | 2.50 | |
Average Assets |
9.64 | 8.66 | 9.20 | 18.22 | |
Average Common Equity |
6.63 | 5.35 | 5.52 | 15.66 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates